Israel's Protalix Q2 revenue rises on Elfabrio sales, reiterates 2026 outlook

Protalix BioTherapeutics

12/08/2026 12:02

Overview
Israel biopharma firm's Q2 revenue from selling goods rose yr/yr, driven by Elfabrio sales
Q2 net income increased to $3.8 mln from $164,000 a yr earlier
Company reiterated full-year 2026 revenue guidance of $78 mln to $83 mln

Outlook
Protalix sees 2026 total revenue of $78 mln to $83 mln, including $25 mln milestone
Company expects 2026 Elfabrio sales, excluding milestones, of $33 mln to $35 mln
Protalix expects 2026 Elelyso sales of $20 mln to $23 mln

Result Drivers
ELFABRIO SALES - Co said Q2 revenue growth was driven primarily by continued penetration and growth of Elfabrio, especially through partnership with Chiesi
HIGHER SALES TO FIOCruz - Co reported increased sales to Fiocruz (Brazil) contributed to revenue growth, partially offset by lower Pfizer purchases
COST OF REVENUES - Q2 cost of revenues rose, mainly reflecting increased sales to Chiesi and Fiocruz, partially offset by lower sales to Pfizer

Company press release: ID:nPn77HRNRa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
 
$19.90 mln
 
Q2 EPS
 
$0.05
 
Q2 Net Income
 
$3.78 mln
 
Q2 Operating Income
 
$4.67 mln
 
Q2 Pretax Profit
 
$4.86 mln
 

Analyst Coverage
The one available analyst rating on the shares is "buy"
The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 13 three months ago

Reuters Recommended Reads
Aug 12 - Formycon H1 revenue rises sharply on milestone payments, EBITDA loss narrows
Aug 12 - Liquidia Q2 revenue jumps on YUTREPIA sales
Aug 11 - Cardinal Health forecasts full-year profit above estimates on specialty drug strength

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)